Tech Company Financing Transactions
Merrimack Pharmaceuticals Funding Round
Sorenson Development and Unilever participated in a $37.3 million Series D funding round for Merrimack Pharmaceuticals. This VC investment round closed on 4/20/2005.
Transaction Overview
Company Name
Announced On
4/20/2005
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$37,300,000
Round
Series D
Investors
Sorenson Development (Gary Crocker)
Proceeds Purpose
The financing was
comprised of $28.3 million of Series D Preferred Stock and a $9
million venture loan.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. 14th Floor B7201
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) is a biotechnology company based in Cambridge, Massachusetts. We are dedicated to the discovery and development of innovative therapies for the treatment of autoimmune disease and cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Mulroy
Chief Financial Officer
Yasir Al-Wakeel
VP - Bus. Development
Peter Laivins
VP - General Counsel
Jeffrey Munsie
VP - Operations
William Mcclements
Browse more venture capital transactions:
Prev: 4/20/2005: Intergis venture capital transaction
Next: 4/21/2005: Molecular Insight Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs